ADX-914

DRUG2 trials

Sponsors

Q32 Bio Inc.

Conditions

Atopic DermatitisSafety Issues

Phase 1

Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers

CompletedNCT04485481

Q32 Bio Inc.Safety Issues

Start: 2020-09-08End: 2022-01-12Updated: 2022-07-28

Phase 2

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

Active, not recruitingNCT05509023

Q32 Bio Inc.Atopic Dermatitis

Start: 2022-09-30End: 2024-12-31Target: 102Updated: 2024-10-03